Hanne Ostergaard, Director, CRINA
Chair: Reza Mirzaei
8:45 AM: Cécilia Bernier, "FABP7 inhibition and DHA supplementation remodel amino acid and mitochondrial lipid metabolism in glioblastoma stem-like cells"
8:55 AM: Arkapravo Chattopadhyay, "Generative AI-based model surpasses traditional design in engineering nav1.5-selective, anti-metastatic therapeutics"
9:05 AM: Dante Terino, "Characterizing reovirus replication and immune activation across heterogeneous tumor microdomains"
9:15 AM: Noorossadat Seyyedi, "The role of mutant p53R175H in de novo activation of von Willebrand factor expression in tumor cells"
9:25 AM: Alicia O’Brien, "Protection against arsenic and selenium by ATP binding cassette transporter ABCC4 in HEK293 and HepaRG cells"
9:35 AM: Noah Wood, "FABP12-induced polyploidy and metabolic plasticity in metastatic prostate cancer"
Chair: Jenilee Woodfield
8:45 AM: Rama Al-Sheikh-Ali, "Investigating RNF114 and RNF166 as novel homologous recombination regulators and therapeutic vulnerabilities in ovarian cancer"
8:55 AM: Emmanuel Alimo, "Circadian regulation of immunotherapy: CD71+ erythroid cells as time-dependent mediators of PD-1/PD-L1 immune suppression"
9:05 AM: Mathew Lubachowski, "Restoration of APC function to resensitize multiple drug resistant breast cancer"
9:15 AM: Mimi Vignjevic, "The role of systemic cancer therapies in cancer-related lymphedema progression"
9:25 AM: Dana Peters, "Inhibition of PTC recognition to enhance cancer immunogenicity"
9:35 AM: Jacob Korodimas, "Investigating the effects of linoleic acid on saturated fatty acid-induced lipotoxicity in cancer-related lymphedema"
Chair: Geetha Menon
11:00 AM: Shay Al-Imarah, "Targeting Glutamine Metabolic Dependencies in DNA Repair - Defined Subtypes of Colorectal Cancer"
11:10 AM: Leslie Ternes, "Multiple myeloma exercise prehabilitation for individuals awaiting and following treatment (MOTIVATE): a randomized controlled feasibility trial"
11:20 AM: Patricia Oliva, "Cross-treatment knowledge transfer: An autosegmentation model for brachytherapy developed with external beam radiotherapy contours"
11:30 AM: Ore Aina, "Improving radiation therapy for cervical cancer using a novel senolytic strategy"
11:40 AM: Lauren Smart, "Towards developing an institutional ultra-fast dose calculation algorithm with transformer neural networks"
11:50 AM: Angie Chen, "Effect of TFAM dysfunction on cGAS/STING activation in colorectal cancer subtypes"
Chair: Lisa Willis
11:00 AM: Elizabeth Reid, "Spatial protein-barcoded CRISPR screening identifies glioblastoma–macrophage communication pathways for therapeutic macrophage reprogramming"
11:10 AM: Ahmed Abdelfattah, "Nanodelivery of a novel ERCC1/XPF inhibitor (B9) for sensitization of lung cancer to carboplatin"
11:20 AM: Kirat Sandhu, "Polymeric co-delivery of TRAIL mRNA and anti-apoptotic siRNAs for inducing apoptosis in NSCLC"
11:30 AM: Gabrielle Provost, "Investigating the Role of NHP2 in Epithelial Ovarian Cancer"
11:40 AM: Shakara Eben-Munro, "Characterizing polysialylated QSOX2 as a cancer-associated glycoform and potential serum biomarker"
11:50 AM: Annie Tong, "Restoring MHC-I loss to overcome immune evasion in dedifferentiated endometrial/ovarian cancer"
Dr. Janessa Laskin will provide an overview of the Personalized Oncogenomics (POG) Program - the BC-wide prospective translational cancer research program that integrates whole genome, transcriptome and germline sequencing into clinical care for patients with a diverse range of cancer types. Dr. Laskin will focus on the challenges and opportunities for this program over the past decade, and lead a discussion on the importance of genomics data sharing and how the Marathon of Hope Cancer Centre Network can help researchers and clinicians learn and improve cancer research and care.
Bio: Dr Laskin is a Medical Oncologist at BC Cancer in Vancouver, and a Clinical Professor in the Department of Medicine at the University of British Columbia. Dr Laskin’s research is focused on genomic and personalized medicine as the clinical program leader for the POG Program. POG is a collaborative translational research effort that uses in-depth genomic sequencing to guide chemotherapy decision-making in a clinically relevant time-frame, through this work she has been an active contributing member of the Marathon of Hope Cancer Centre’s Network initiative.
In this session, Dr. Janessa Laskin, Dr. Randeep Sangha, Dr. Cheng-Han Lee and Danielle Simonot will explore strategies for how to integrate biomedical research into clinical trials.
Moderator: Dr. Paula Robson
Chair: Hanne Ostergaard
Taylor Holtom, "The influence of interleukin-6 on anti-tumor immunity in different colorectal cancer subtypes"
Gugulethu Khumalo, "Mechanosensitive progesterone receptor signaling: defining S81 as a molecular link between tumor mechanics and breast cancer progression"
William Li, "The influence of Multidrug Resistance Protein 1 (MRP1/ABCC1) phosphorylation on the transport of the human carcinogen arsenic"
Anita Minootan, "Machine learning-guided process optimization of a customized millifluidic platform for amphiphilic block copolymer micelle production in anti-cancer drug delivery"
Isabelle Nechala, "Preclinical evaluation demonstrates therapeutic potential for MEK Inhibition in NF1- deficient high-grade serous tubo-ovarian carcinomas"
Amreen Podruzny, "A multiplex imaging approach for the spatial characterization of polysialic acid in lung cancer"
Jazmin Reyes-Martinez, "Linking PROTAC uptake to FOXM1 protein degradation in lung cancer cells"
Elham Zeinali, "Immunomodulatory drugs-responsive degradation of the E3 ubiquitin ligase RNF166 underlies clinical utility in multiple myeloma"